for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-AstraZeneca Says Calquence Approved In The EU For CLL

Nov 9 (Reuters) - AstraZeneca PLC:

* ASTRAZENECA PLC - CALQUENCE APPROVED IN THE EU FOR CLL

* ASTRAZENECA - CALQUENCE APPROVED IN EU FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA

* ASTRAZENECA- APPROVAL BY EUROPEAN COMMISSION WAS BASED ON POSITIVE RESULTS FROM TWO PHASE III CLINICAL TRIALS

* ASTRAZENECA - CALQUENCE SHOWED SUPERIOR PROGRESSION-FREE SURVIVAL, FAVOURABLE TOLERABILITY IN PREVIOUSLY UNTREATED AND RELAPSED OR REFRACTORY PATIENTS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up